Can We Predict Which Women Will Benefit from Tamoxifen

Abstract

To prevent breast cancer, over 200,000 women are now taking tamoxifen and similar selective estrogen receptor modifiers (SERM). We have laboratory data that shows that approximately 30% of women have defects in their breast cell's estrogen receptor or in its intracellular signaling mechanism. As a result, these women may not experience the antineoplastic effect of tamoxifen on breast cancer risk but only its side effects. We propose that contrast enhanced magnetic resonance imaging (CE MRI) can detect this defect. CE MRI will be performed on postmenopausal women on tamoxifen therapy. Despite very extensive procedures for recruiting subjects, we have not recruited enough to perform the planned research.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2002
Accession Number
ADA412105

Entities

People

  • Peter L. Davis

Organizations

  • University of Pittsburgh

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Alkenes
  • Breast Cancer
  • Carcinoma
  • Contrast
  • Estrogens
  • Health Services
  • Inclusions
  • Institutional Review Board
  • Magnetic Resonance
  • Magnetic Resonance Imaging
  • Medical Personnel
  • Neoplasms
  • Personnel Management
  • Physicians
  • Resonance
  • Side Effects

Fields of Study

  • Medicine

Readers

  • Breast cancer cell signaling and growth regulation.
  • Medical Imaging.
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.